Nevertheless, data from a Phase II clinical trial conducted in Japan indicated that serious adverse events associated with the combination of gefitinib and bevacizumab included grade 3 rash, hypertension, elevated aspartate aminotransferase and alanine aminotransferase, proteinuria, intracranial bleeding, and grade 4 gastrointestinal perforation [34]. This evidence concerns the gene GPT and Hypertension.